CurrentUnitedHealthcarePolicy N/A

Trientine (Syprine) prior authorization

Defines UnitedHealthcare pharmacy prior authorization requirements for Syprine (trientine hydrochloride) and generic trientine hydrochloride for treatment of Wilson's disease; applies to members whose benefit plan uses this program.

Policy Summary

PayerUnitedHealthcare

PolicyTrientine (Syprine) prior authorization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis of Wilson's disease plus trial and intolerance, failure, or contraindication to penicillamine.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsinitial authorization period

12 monthsre-authorization period

Syprine typically excludedbrand coverage note

2025 P 1135-13program id

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy

inv-10: Initial Therapy

Initial approval criteria

Initial Therapy: Diagnosis of Wilson's disease (hepatolenticular degeneration).

Initial Therapy: Documented history of intolerance, failure, or contraindication to penicillamine is required prior to coverage.

12-month authorization.

Continuation / Reauthorization Criteria

inv-11: Continuation Therapy

Reauthorization requirement

Continuation: Documentation of positive clinical response to therapy is required for reauthorization.

Reauthorization will be issued for 12 months.

Provider Actions and Documentation Required

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for Syprine (trientine hydrochloride) and generic trientine hydrochloride. Initial approvals will be issued for 12 months.

Affected products: Syprine and generic trientine hydrochloride
Initial authorization duration: 12 months

Documentation Required

Tried/Failed Penicillamine

Tried/Failed Penicillamine: Documentation must show a history of intolerance, clinical failure, or a contraindication to penicillamine before Syprine or trientine hydrochloride will be approved.

Acceptable documentation: medical records noting intolerable or life‑threatening side effects, lack of therapeutic response, or documented contraindication to penicillamine

Documentation Required

Reauthorization Documentation

Reauthorization Documentation: For continuation of therapy, documentation of a positive clinical response to Syprine or trientine hydrochloride is required. Reauthorizations will be issued for 12 months.

Required at reauthorization: clinical notes demonstrating improvement or stabilization attributable to therapy
Reauthorization duration: 12 months

Denial Risk

Denial Risk: Lack of a documented diagnosis of Wilson's disease (hepatolenticular degeneration) or absence of documented intolerance, failure, or contraindication to penicillamine may result in denial of the request. Note that some plans typically exclude brand Syprine; verify member‑specific benefit plan coverage.

Required diagnosis: Wilson's disease (hepatolenticular degeneration)
Plan note: Syprine may be excluded for many plans — check plan specifics

Step	Requirement	Coverage
1	Documented history of trial and intolerance, failure, or contraindication to penicillamine (penicillamine must be tried or documentation that it is not appropriate).	Coverage allowed when requirement met

Quantity Limits

Quantity limits for Syprine/trientine

Quantity limits noteSupply limits may be in place for Syprine/trientine (plan-specific).

Frequency/unitPer month — subject to plan-specific limits as applicable.

ExceptionsUnitedHealthcare may approve initial or reauthorization requests based on prior claim/medication history or automated processes despite limits.

ApplicabilityApplies to Syprine (trientine hydrochloride) and generic trientine hydrochloride.

Definitions

Wilson's disease (definition and coverage note)

DefinitionWilson's disease = hepatolenticular degeneration (diagnosis required for coverage).

Coverage requirementDiagnosis of Wilson's disease is required for authorization of Syprine or trientine hydrochloride.

Clinical contextSyprine and trientine are indicated for patients with Wilson's disease who are intolerant of penicillamine and are not interchangeable with penicillamine.

Use conditionShould be used when continued treatment with penicillamine is not possible due to intolerable or life‑threatening side effects.

Background

Trientine (Syprine) is a copper‑chelating agent indicated for the treatment of Wilson's disease (hepatolenticular degeneration), primarily used when patients are intolerant of penicillamine. Coverage under UnitedHealthcare requires documentation of the diagnosis of Wilson's disease and a history of intolerance, failure, or contraindication to penicillamine for initial approval; reauthorization requires documentation of a positive clinical response to therapy. Note that Syprine and trientine hydrochloride are subject to prior authorization and plan‑specific restrictions, and brand Syprine is commonly excluded from coverage—confirm member plan details prior to prescribing.